Ribavirin Bioavailability After Telaprevir Exposure
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin
than in those receiving pegylated-interferon/ribavirin alone. The objective was to measure
the impact of telaprevir on ribavirin bioavailability and to assess the concomitant renal
function.